A web portal for in-silico action potential predictions

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 10-16

  Williams, Geoff ^a   Mirams, Gary R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Action potential; Cardiac safety; Compound screening; High throughput; Mathematical model; Open source

Indexed keywords

CALCIUM CHANNEL; DRUG; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV4.3; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; ION CHANNEL;

ACTION POTENTIAL; ARTICLE; COMPUTER ANALYSIS; COMPUTER GRAPHICS; COMPUTER INTERFACE; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER SIMULATION; DRUG EFFECT; HEART ELECTROPHYSIOLOGY; IC50; ION CURRENT; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; QT PROLONGATION; WEB BROWSER; DRUG EFFECTS; HEART FUNCTION TEST; HUMAN; INTERNET; PATCH CLAMP TECHNIQUE; PROCEDURES; SOFTWARE; THEORETICAL MODEL;

ACTION POTENTIALS; COMPUTER SIMULATION; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HUMANS; INTERNET; ION CHANNELS; MODELS, THEORETICAL; PATCH-CLAMP TECHNIQUES; SOFTWARE;

EID: 84942364799     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.05.002     Document Type: Article

References (37)

1. Beattie K.A., Luscombe C., Williams G., Munoz-Muriedas J., Gavaghan D.J., Cui Y., et al. Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge. Journal of Pharmacological and Toxicological Methods 2013, 68(1):88-96.
2. Black J. Nobel prize lecture: Drugs from emasculated hormones: The principle of syntopic antagonism. Bioscience Reports 1989, 9(3).
3. Cavero I., Holzgrefe H. Comprehensive in vitro proarrhythmia assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative. Expert Opinion on Drug Safety 2014, 13(6):745-758.
4. Cooper J., Corrias A., Gavaghan D.J., Noble D. Considerations for the use of cellular electrophysiology models within cardiac tissue simulations. Progress in Biophysics and Molecular Biology 2011, 107(1):74-80.
5. Cooper J., Spiteri R.J., Mirams G.R. Cellular cardiac electrophysiology modeling with Chaste and CellML. Frontiers in Physiology 2014, 5:511.
6. Elkins R.C., Davies M.R., Brough S.J., Gavaghan D.J., Cui Y., Abi-Gerges N., et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. Journal of Pharmacological and Toxicological Methods 2013, 68(1):112-122.
7. Gintant G. Ions, equations and electrons: The evolving role of computer simulations in cardiac electrophysiology safety evaluations. British Journal of Pharmacology 2012, 167(5):929-931.
8. Grandi E., Pasqualini F.S., Bers D.M. A novel computational model of the human ventricular action potential and Ca transient. Journal of Molecular and Cellular Cardiology 2010, 48:112-121.
9. Hindmarsh A.C., Brown P.N., Grant K.E., Lee S.L., Serban R., Shumaker D.E., et al. SUNDIALS: Suite of nonlinear and differential/algebraic equation solvers. ACM Transactions on Mathematical Software (TOMS) 2005, 31(3):363-396.
10. Hodgkin A.L., Huxley A.F. A quantitative description of membrane current and its application to conduction and excitation in nerve. Journal of Physiology 1952, 117:500-544.
11. ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2015, (URL http://goo.gl/VDUKmZ).
12. ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals 2015, (URL http://goo.gl/iidGkY).
13. Irvine L.A., Jafri M.S., Winslow R.L. Cardiac sodium channel markov model with temperature dependence and recovery from inactivation. Biophysical Journal 1999, 76(4):1868-1885.
14. Kleiman R.B., Shah R.R., Morganroth J. Replacing the thorough qt study: Reflections of a baby in the bath water. British Journal of Clinical Pharmacology 2014, 78(2):195-201.
15. Kramer J., Obejero-Paz C.A., Myatt G., Kuryshev Y.A., Bruening-Wright A., Verducci J.S., et al. MICE models: superior to the HERG model in predicting Torsade de Pointes. Scientific Reports 2013, 3:2100.
16. Lloyd C.M., Lawson J.R., Hunter P.J., Nielsen P.F. The CellML model repository. Bioinformatics 2008, 24(18):2122-2123.
17. Mahajan A., Shiferaw Y., Sato D., Baher A., Olcese R., Xie L., et al. A rabbit ventricular action potential model replicating cardiac dynamics at rapid heart rates. Biophysical Journal 2008, 94(2):392-410.
18. Mirams G.R. Pro-arrhyhthmia metrics from in-silico action potential models 2015, 1396510. Figshare, (URL http://dx.doi.org/10.6084/m9.figshare.1396510).
19. Mirams G.R., Arthurs C.J., Bernabeu M.O., Bordas R., Cooper J., Corrias A., et al. Chaste: An open source c++ library for computational physiology and biology. PLoS Computational Biology 2013, 9(3):e1002970.
20. Mirams G.R., Cui Y., Sher A., Fink M., Cooper J., Heath B.M., et al. Simulation of the effect of compounds on multiple ion channels provides improved early prediction of their clinical torsadogenic risk. Cardiovascular Research 2011, 91(1):53-61.
21. Mirams G.R., Davies M.R., Brough S.J., Bridgland-Taylor M.H., Cui Y., Gavaghan D.J., et al. Prediction of thorough QT study results using action potential simulations based on ion channel screens. Journal of Pharmacological & Toxicological Methods 2014, 70(3):246-254.
22. Mitcheson J.S., Perry M.D. Molecular determinants of high-affinity drug binding to herg channels. Current Opinion in Drug Discovery & Development 2003, 6(5):667-674.
23. Moreno J.D., Yang P.-C., Bankston J.R., Grandi E., Bers D.M., Kass R.S., et al. Ranolazine for congenital and acquired late INa-linked arrhythmias in silico pharmacological screening. Circulation Research 2013, 113(7):e50-e61.
24. Noble D. Cardiac action and pacemaker potentials based on the Hodgkin-Huxley equations. Nature 1960, 188:495-497.
25. Noble D., Noble P.J. Late sodium current in the pathophysiology of cardiovascular disease: Consequences of sodium-calcium overload. British Medical Journal 2006, 92(Suppl. 4):iv1-iv5.
26. Noble D., Rudy Y. Models of cardiac ventricular action potentials: Iterative interaction between experiment and simulation. Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences 2001, 359(1783):1127-1142.
27. Noujaim S.F., Kaur K., Milstein M., Jones J.M., Furspan P., Jiang D., et al. A null mutation of the neuronal sodium channel nav1. 6 disrupts action potential propagation and excitation-contraction coupling in the mouse heart. The FASEB Journal 2012, 26(1):63-72.
28. O'Hara T., Virág L., Varró A., Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation. PLoS Computational Biology 2011, 7(5):e1002061.
29. Paci M., Hyttinen J., Aalto-Setälä K., Severi S. Computational models of ventricular-and atrial-like human induced pluripotent stem cell derived cardiomyocytes. Annals of Biomedical Engineering 2013, 41(11):2334-2348.
30. Pathmanathan P., Gray R.A. Verification of computational models of cardiac electro-physiology. International Journal of Numerical Methods in Biomedical Engineering 2013, 30(5):525-544.
31. Pollard C., Gerges N., Bridgland-Taylor M., Easter A., Hammond T., Valentin J. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. British Journal of Pharmacology 2010, 159(1):12-21.
32. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58(1):32-45.
33. Sager P.T., Gintant G., Turner J.R., Pettit S., Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal 2014, 167(3):292-300.
34. Sanguinetti M., Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440(7083):463-469.
35. Shannon T., Wang F., Puglisi J., Weber C., Bers D. A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophysical Journal 2004, 87(5):3351-3371.
36. Ten Tusscher K., Panfilov A. Alternans and spiral breakup in a human ventricular tissue model. American Journal of Physiology. Heart and Circulatory Physiology 2006, 291(3):1088-1100.
37. Yang T., Atack T.C., Stroud D.M., Zhang W., Hall L., Roden D.M. Blocking scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circulation Research 2012, 111(3). 332-332.